Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial

Journal of Bone and Mineral Research

Volumn 13, Issue 11, 1998, Pages 1747-1754

  Lufkin, Edward G ^a   Whitaker, Michael D ^b   Nickelsen, Thomas ^c   Argueta, Rodolfo ^b   Caplan, Robert H ^d   Knickerbocker, Ronald K ^c   Riggs, B Lawrence ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; CALCIUM; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; PROSPECTIVE STUDIES; RALOXIFENE; SPINAL FRACTURES;

EID: 0031755910     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.11.1747     Document Type: Article

References (26)

1. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA 1984 Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo-[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl] [4-[2-(1-piperidinyl) ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 27:1057-1066.
2. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10:119-131.
3. Yang NN, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17 β-estradiol and raloxifene. Science 273: 1222-1225.
4. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856.
5. Davidson NE 1992 Tamoxifen - Panacea or Pandora's box? N Engl J Med 326:885-886.
6. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636-641.
7. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69.
8. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835-842.
9. Kao PC, Heser DW 1984 Simultaneous determination of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D from a single sample by dual-cartridge extraction. Clin Chem 30:56-61.
10. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
11. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
12. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
13. Mazess RB, Gifford CA, Bisek JP, Barden HS, Hanson JA 1991 DEXA measurement of spine density in the lateral projection. I: Methodology. Calcif Tissue Int 49:235-239.
14. Lindsay R, Tohme JF 1990 Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295.
15. Marx CW, Dailey GE III, Cheney C, Vint VC II, Muchmore DB 1992 Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Miner Res 7:1275-1279.
16. Riggs BL, Melton LJ III, O'Fallon WM 1996 Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18 (Suppl):197S-201S.
17. Kannel WB 1987 Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J 114:413-419.
18. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C 1997 Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96:1964-1969.
19. Clarkson TB, Cline JM, Williams JK, Anthony MS 1997 Gonadal hormone substitutes: Effects on the cardiovascular system. Osteoporos Int 7 (Suppl 1):S52-S57.
20. Eastell R 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746.
21. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R 1993 Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881-889.
22. Lufkin EG, Riggs BL 1996 Three-year followup on effects of transdermal estrogen. Ann Intern Med 125:77.
23. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR 1992 Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037.
24. Sherwin BB 1996 Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol 87 (Suppl 2): 20S-26S.
25. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.
26. Seachrist L 1995 What risk hormones? Conflicting studies reveal problems in pinning down breast cancer risks. Science 148:94-95.